Published in Eur J Nucl Med Mol Imaging on December 01, 2009
FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0. Eur J Nucl Med Mol Imaging (2014) 2.79
Positron Emission Tomography (PET) in Oncology. Cancers (Basel) (2014) 1.41
Approaches for the optimization of MR protocols in clinical hybrid PET/MRI studies. MAGMA (2012) 0.90
Appropriate use criteria for amyloid PET imaging cannot replace guidelines: on behalf of the European Association of Nuclear Medicine. Eur J Nucl Med Mol Imaging (2013) 0.90
The metabolic signature of C9ORF72-related ALS: FDG PET comparison with nonmutated patients. Eur J Nucl Med Mol Imaging (2014) 0.90
Validation of an optimized SPM procedure for FDG-PET in dementia diagnosis in a clinical setting. Neuroimage Clin (2014) 0.89
Multiclass classification of FDG PET scans for the distinction between Parkinson's disease and atypical parkinsonian syndromes. Neuroimage Clin (2013) 0.87
The potential roles of 18F-FDG-PET in management of acute stroke patients. Biomed Res Int (2013) 0.84
Volume of interest-based [18F]fluorodeoxyglucose PET discriminates MCI converting to Alzheimer's disease from healthy controls. A European Alzheimer's Disease Consortium (EADC) study. Neuroimage Clin (2014) 0.84
Electroacupuncture stimulation at sub-specific acupoint and non-acupoint induced distinct brain glucose metabolism change in migraineurs: a PET-CT study. J Transl Med (2014) 0.83
Positron emission tomography-computer tomography scan used as a monitoring tool following cellular therapy in cerebral palsy and mental retardation-a case report. Case Rep Neurol Med (2013) 0.83
Neural circuit modulation during deep brain stimulation at the subthalamic nucleus for Parkinson's disease: what have we learned from neuroimaging studies? Brain Connect (2013) 0.82
Early and phasic cortical metabolic changes in vestibular neuritis onset. PLoS One (2013) 0.82
American College of Radiology and Society of Nuclear Medicine and Molecular Imaging Joint Credentialing Statement for PET/MR Imaging: Brain. J Nucl Med (2015) 0.81
The role of functional neuroimaging in pre-surgical epilepsy evaluation. Front Neurol (2014) 0.81
PET imaging of the brain serotonin transporters (SERT) with N,N-dimethyl-2-(2-amino-4-[18F]fluorophenylthio)benzylamine (4-[18F]-ADAM) in humans: a preliminary study. Eur J Nucl Med Mol Imaging (2012) 0.80
Brain metabolic changes in Hodgkin disease patients following diagnosis and during the disease course: An (18)F-FDG PET/CT study. Oncol Lett (2014) 0.79
Cerebrospinal fluid lactate levels and brain [18F]FDG PET hypometabolism within the default mode network in Alzheimer's disease. Eur J Nucl Med Mol Imaging (2016) 0.77
Striatal hypometabolism in premanifest and manifest Huntington's disease patients. Eur J Nucl Med Mol Imaging (2016) 0.77
PET studies in epilepsy. Am J Nucl Med Mol Imaging (2015) 0.77
Plasma antioxidants and brain glucose metabolism in elderly subjects with cognitive complaints. Eur J Nucl Med Mol Imaging (2013) 0.77
Construction and comparative evaluation of different activity detection methods in brain FDG-PET. Biomed Eng Online (2015) 0.77
Transient and chronic seizure-induced inflammation in human focal epilepsy. Epilepsia (2016) 0.77
Cortico-subcortical metabolic correlates of olfactory processing in healthy resting subjects. Sci Rep (2014) 0.77
Influence of P-Glycoprotein Inhibition or Deficiency at the Blood-Brain Barrier on (18)F-2-Fluoro-2-Deoxy-D-glucose ( (18)F-FDG) Brain Kinetics. AAPS J (2015) 0.77
Cerebellar metabolic involvement and its correlations with clinical parameters in vestibular neuritis. J Neurol (2014) 0.76
Functional Plasticity after Unilateral Vestibular Midbrain Infarction in Human Positron Emission Tomography. PLoS One (2016) 0.76
Role of functional imaging in the development and refinement of invasive neuromodulation for psychiatric disorders. World J Radiol (2014) 0.76
Comparison between Early-Onset and Late-Onset Alzheimer's Disease Patients with Amnestic Presentation: CSF and (18)F-FDG PET Study. Dement Geriatr Cogn Dis Extra (2016) 0.76
Aspects of cerebral plasticity related to clinical features in acute vestibular neuritis: a "starting point" review from neuroimaging studies. Acta Otorhinolaryngol Ital (2016) 0.75
Validation of true low-dose (18)F-FDG PET of the brain. Am J Nucl Med Mol Imaging (2016) 0.75
Glucose-corrected standardized uptake value in the differentiation of high-grade glioma versus post-treatment changes. Nucl Med Commun (2015) 0.75
Cortical metabolic arrangement during olfactory processing: proposal for a 18F FDG PET/CT methodological approach. Medicine (Baltimore) (2014) 0.75
Optimization of brain PET imaging for a multicentre trial: the French CATI experience. EJNMMI Phys (2016) 0.75
Impact of attenuation correction on clinical [(18)F]FDG brain PET in combined PET/MRI. EJNMMI Res (2016) 0.75
Nuclear Medicine Imaging in Pediatric Neurology. Mol Imaging Radionucl Ther (2016) 0.75
The use of fluorine-18 fluorodeoxyglucose positron emission tomography for imaging human motor neuronal activation in the brain. Exp Ther Med (2015) 0.75
(18)F-fluorodeoxyglucose and (18)F-flumazenil positron emission tomography in patients with refractory epilepsy. Radiol Oncol (2016) 0.75
The Role of Single-Subject Brain Metabolic Patterns in the Early Differential Diagnosis of Primary Progressive Aphasias and in Prediction of Progression to Dementia. J Alzheimers Dis (2016) 0.75
Hypothalamic dysfunction is related to sleep impairment and CSF biomarkers in Alzheimer's disease. J Neurol (2017) 0.75
Mapping brain morphological and functional conversion patterns in predementia late-onset bvFTD. Eur J Nucl Med Mol Imaging (2016) 0.75
Effect of hyperglycemia on brain and liver (18)F-FDG standardized uptake value (FDG SUV) measured by quantitative positron emission tomography (PET) imaging. Biomed Pharmacother (2017) 0.75
18F-FDG PET diagnostic and prognostic patterns do not overlap in Alzheimer's disease (AD) patients at the mild cognitive impairment (MCI) stage. Eur J Nucl Med Mol Imaging (2017) 0.75
Cerebral metabolic changes related to clinical parameters in idiopathic anosmic patients during olfactory stimulation: a pilot investigation. Eur Arch Otorhinolaryngol (2017) 0.75
The need of standardization and of large clinical studies in an emerging indication of [(18)F]FDG PET: the autoimmune encephalitis. Eur J Nucl Med Mol Imaging (2016) 0.75
Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria. Lancet Neurol (2007) 18.62
A diagnostic approach in Alzheimer's disease using three-dimensional stereotactic surface projections of fluorine-18-FDG PET. J Nucl Med (1995) 4.44
Discrimination between Alzheimer dementia and controls by automated analysis of multicenter FDG PET. Neuroimage (2002) 3.88
Multicenter standardized 18F-FDG PET diagnosis of mild cognitive impairment, Alzheimer's disease, and other dementias. J Nucl Med (2008) 2.92
PET: the merging of biology and imaging into molecular imaging. J Nucl Med (2000) 2.15
Automated detection of the intercommissural line for stereotactic localization of functional brain images. J Nucl Med (1993) 1.93
Metabolic correlates of levodopa response in Parkinson's disease. Neurology (2001) 1.50
Positron emission tomography imaging in dementia. Br J Radiol (2007) 1.42
The use of SPECT and PET in routine clinical practice in epilepsy. Curr Opin Neurol (2007) 1.41
Rapid scanning protocol for brain (18)F-FDG PET: a validation study. J Nucl Med (2005) 1.41
FDG PET in the differential diagnosis of parkinsonian disorders. Neuroimage (2005) 1.40
Abnormal metabolic networks in atypical parkinsonism. Mov Disord (2008) 1.39
Regional differences in cerebral blood flow and glucose utilization in diabetic man: the effect of insulin. J Cereb Blood Flow Metab (1998) 1.26
Preoperative evaluation of 54 gliomas by PET with fluorine-18-fluorodeoxyglucose and/or carbon-11-methionine. J Nucl Med (1998) 1.25
Normal variants, artefacts and interpretative pitfalls in PET imaging with 18-fluoro-2-deoxyglucose and carbon-11 methionine. Eur J Nucl Med (1999) 1.24
Radiation exposure during transmission measurements: comparison between CT- and germanium-based techniques with a current PET scanner. Eur J Nucl Med Mol Imaging (2003) 1.11
No effect of insulin on glucose blood-brain barrier transport and cerebral metabolism in humans. Diabetes (1999) 1.10
Procedure guideline for tumor imaging using fluorine-18-FDG. Society of Nuclear Medicine. J Nucl Med (1998) 1.05
The FDG lumped constant in normal human brain. J Nucl Med (2002) 1.04
Resting regional cerebral glucose metabolism in advanced Parkinson's disease studied in the off and on conditions with [(18)F]FDG-PET. Mov Disord (2001) 1.02
18F-FDG PET studies in patients with extratemporal and temporal epilepsy: evaluation of an observer-independent analysis. J Nucl Med (1999) 0.99
European Association of Nuclear Medicine procedure guidelines for brain imaging using [(18)F]FDG. Eur J Nucl Med Mol Imaging (2002) 0.97
Individual metabolic anatomy of repeating words demonstrated by MRI-guided positron emission tomography. Neurosci Lett (1994) 0.94
Localisation of motor areas in brain tumour patients: a comparison of preoperative [18F]FDG-PET and intraoperative cortical electrostimulation. Eur J Nucl Med (2001) 0.90
Measurement of regional cerebral glucose utilization with fluorine-18-FDG and PET in heterogeneous tissues: theoretical considerations and practical procedure. J Nucl Med (1993) 0.88
Estimated radiation dose to the newborn in FDG-PET studies. J Nucl Med (1996) 0.85
Clinical evaluation of interictal fluorine-18-fluorodeoxyglucose PET in partial epilepsy. J Nucl Med (1993) 0.85
The role of positron emission tomography with [18F]fluorodeoxyglucose in the evaluation of the epilepsies. Neuroimaging Clin N Am (2004) 0.84
The effect of vigabatrin (gamma-vinyl GABA) on cerebral blood flow and metabolism. Neurology (1999) 0.83
Clinical brain radionuclide imaging studies. Semin Nucl Med (1995) 0.78
Ethical clinical practice of functional brain imaging. Society of Nuclear Medicine Brain Imaging Council. J Nucl Med (1996) 0.76
[Comparison of different methods for attenuation correction in brain PET: effect on the calculation of the metabolic rate of glucose]. Nuklearmedizin (2000) 0.75
[Clinical value of positron emission tomography in neuromedicine. Position paper on results of an interdisciplinary consensus conference]. Nervenarzt (1998) 0.75
FDG PET and PET/CT: EANM procedure guidelines for tumour PET imaging: version 1.0. Eur J Nucl Med Mol Imaging (2010) 7.82
Idiopathic hyposmia as a preclinical sign of Parkinson's disease. Ann Neurol (2004) 3.79
18F-flutemetamol amyloid imaging in Alzheimer disease and mild cognitive impairment: a phase 2 trial. Ann Neurol (2010) 3.49
Sensitivity and specificity of dopamine transporter imaging with 123I-FP-CIT SPECT in dementia with Lewy bodies: a phase III, multicentre study. Lancet Neurol (2007) 3.25
Free fatty acid depletion acutely decreases cardiac work and efficiency in cardiomyopathic heart failure. Circulation (2006) 3.12
Correlation between dopamine D(2) receptors in the ventral striatum and central processing of alcohol cues and craving. Am J Psychiatry (2004) 2.84
Cerebral amyloid-β PET with florbetaben (18F) in patients with Alzheimer's disease and healthy controls: a multicentre phase 2 diagnostic study. Lancet Neurol (2011) 2.84
FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0. Eur J Nucl Med Mol Imaging (2014) 2.79
Nodal/Activin signaling drives self-renewal and tumorigenicity of pancreatic cancer stem cells and provides a target for combined drug therapy. Cell Stem Cell (2011) 2.78
Combined targeted treatment to eliminate tumorigenic cancer stem cells in human pancreatic cancer. Gastroenterology (2009) 2.64
Pre-therapeutic dosimetry and biodistribution of 86Y-DOTA-Phe1-Tyr3-octreotide versus 111In-pentetreotide in patients with advanced neuroendocrine tumours. Eur J Nucl Med Mol Imaging (2004) 2.45
Visualizing out-of-body experience in the brain. N Engl J Med (2007) 2.44
Status gelasticus after temporal lobectomy: ictal FDG-PET findings and the question of dual pathology involving hypothalamic hamartomas. Epilepsia (2005) 2.43
Overexpression of Glut-1 and increased glucose metabolism in tumors are associated with a poor prognosis in patients with oral squamous cell carcinoma. Cancer (2003) 2.37
Increased fibrillar amyloid-{beta} burden in normal individuals with a family history of late-onset Alzheimer's. Proc Natl Acad Sci U S A (2010) 2.32
Cognitive reserve hypothesis: Pittsburgh Compound B and fluorodeoxyglucose positron emission tomography in relation to education in mild Alzheimer's disease. Ann Neurol (2008) 2.24
Gender differences in Parkinson's disease. J Neurol Neurosurg Psychiatry (2006) 2.23
Assessment of beta-amyloid in a frontal cortical brain biopsy specimen and by positron emission tomography with carbon 11-labeled Pittsburgh Compound B. Arch Neurol (2008) 2.19
18F-FDG PET/CT identifies patients at risk for future vascular events in an otherwise asymptomatic cohort with neoplastic disease. J Nucl Med (2009) 2.19
Optimized in vivo detection of dopamine release using 18F-fallypride PET. J Nucl Med (2012) 2.18
EANM procedure guidelines for brain neurotransmission SPECT using (123)I-labelled dopamine transporter ligands, version 2. Eur J Nucl Med Mol Imaging (2010) 2.09
Regional analysis of FDG and PIB-PET images in normal aging, mild cognitive impairment, and Alzheimer's disease. Eur J Nucl Med Mol Imaging (2008) 2.04
The acyclic CB1R inverse agonist taranabant mediates weight loss by increasing energy expenditure and decreasing caloric intake. Cell Metab (2008) 1.94
Intravenous immunoglobulin for treatment of mild-to-moderate Alzheimer's disease: a phase 2, randomised, double-blind, placebo-controlled, dose-finding trial. Lancet Neurol (2013) 1.84
Trimetazidine, a metabolic modulator, has cardiac and extracardiac benefits in idiopathic dilated cardiomyopathy. Circulation (2008) 1.82
[18F]MK-9470, a positron emission tomography (PET) tracer for in vivo human PET brain imaging of the cannabinoid-1 receptor. Proc Natl Acad Sci U S A (2007) 1.73
Phase 1 study of the Pittsburgh compound B derivative 18F-flutemetamol in healthy volunteers and patients with probable Alzheimer disease. J Nucl Med (2009) 1.70
Whole-body biodistribution and radiation dosimetry of 18F-GE067: a radioligand for in vivo brain amyloid imaging. J Nucl Med (2009) 1.65
Assessment of islet specificity of dihydrotetrabenazine radiotracer binding in rat pancreas and human pancreas. J Nucl Med (2010) 1.61
Frontal and temporal dopamine release during working memory and attention tasks in healthy humans: a positron emission tomography study using the high-affinity dopamine D2 receptor ligand [11C]FLB 457. J Neurosci (2005) 1.58
Real versus imagined locomotion: a [18F]-FDG PET-fMRI comparison. Neuroimage (2009) 1.56
Cyclicity of spontaneous recurrent seizures in pilocarpine model of temporal lobe epilepsy in rat. Exp Neurol (2007) 1.55
The effects of d-amphetamine on extrastriatal dopamine D2/D3 receptors: a randomized, double-blind, placebo-controlled PET study with [11C]FLB 457 in healthy subjects. Eur J Nucl Med Mol Imaging (2008) 1.55
Quantitative and qualitative analysis of metabolic response at interim positron emission tomography scan combined with International Prognostic Index is highly predictive of outcome in diffuse large B-cell lymphoma. Leuk Lymphoma (2013) 1.54
18F-Fluoroethylcholine PET/CT identifies lymph node metastasis in patients with prostate-specific antigen failure after radical prostatectomy but underestimates its extent. Eur Urol (2012) 1.54
Association of low striatal dopamine d2 receptor availability with nicotine dependence similar to that seen with other drugs of abuse. Am J Psychiatry (2008) 1.53
Dopamine transporter imaging in autopsy-confirmed Parkinson's disease and multiple system atrophy. Mov Disord (2011) 1.53
Longitudinal microPET imaging of brain glucose metabolism in rat lithium-pilocarpine model of epilepsy. Exp Neurol (2009) 1.52
[11C] methionine and [18F] fluorodeoxyglucose PET in the follow-up of glioblastoma multiforme. J Neurooncol (2007) 1.51
Increased ventral striatal CB1 receptor binding is related to negative symptoms in drug-free patients with schizophrenia. Neuroimage (2013) 1.48
Brain type 1 cannabinoid receptor availability in patients with anorexia and bulimia nervosa. Biol Psychiatry (2011) 1.48
FET PET for the evaluation of untreated gliomas: correlation of FET uptake and uptake kinetics with tumour grading. Eur J Nucl Med Mol Imaging (2007) 1.47
Proposal for the standardisation of multi-centre trials in nuclear medicine imaging: prerequisites for a European 123I-FP-CIT SPECT database. Eur J Nucl Med Mol Imaging (2012) 1.47
Differentiation of frontotemporal dementia from dementia with Lewy bodies using FP-CIT SPECT. J Neurol Neurosurg Psychiatry (2012) 1.47
Effects of intravenous glucose on dopaminergic function in the human brain in vivo. Synapse (2007) 1.46
Long-term assessment of striatal dopamine transporters in Parkinsonian patients with intrastriatal embryonic mesencephalic grafts. Eur J Nucl Med Mol Imaging (2006) 1.46
EANM procedure guideline for brain perfusion SPECT using 99mTc-labelled radiopharmaceuticals, version 2. Eur J Nucl Med Mol Imaging (2009) 1.45
Cerebral impairment in chronic solvent-induced encephalopathy. Ann Neurol (2008) 1.45
Paroxysmal exercise-induced dyskinesia and epilepsy is due to mutations in SLC2A1, encoding the glucose transporter GLUT1. Brain (2008) 1.41
The use of SPECT and PET in routine clinical practice in epilepsy. Curr Opin Neurol (2007) 1.41
Tc-99m sestamibi single photon emission computed tomography for guiding percutaneous coronary intervention in patients with multivessel disease: a comparison with quantitative coronary angiography and fractional flow reserve. Int J Cardiovasc Imaging (2009) 1.41
Correlation of alcohol craving with striatal dopamine synthesis capacity and D2/3 receptor availability: a combined [18F]DOPA and [18F]DMFP PET study in detoxified alcoholic patients. Am J Psychiatry (2005) 1.41
Patient and caregiver perspectives of quality of life in dementia. An investigation of the relationship to behavioural and psychological symptoms in dementia. Dement Geriatr Cogn Disord (2008) 1.41
Molecular imaging of gliomas with PET: opportunities and limitations. Neuro Oncol (2011) 1.40
Interesting image. Unusual parathyroid adenoma avid for both Tc-99m sestamibi and I-123 iodine. Clin Nucl Med (2010) 1.38
Neuropsychiatric syndromes in dementia. Results from the European Alzheimer Disease Consortium: part I. Dement Geriatr Cogn Disord (2007) 1.38
5-Aminolevulinic acid is a promising marker for detection of anaplastic foci in diffusely infiltrating gliomas with nonsignificant contrast enhancement. Cancer (2010) 1.35
Analysis of 18F-FET PET for grading of recurrent gliomas: is evaluation of uptake kinetics superior to standard methods? J Nucl Med (2006) 1.33
Clinical testing of an optimized software solution for an automated, observer-independent evaluation of dopamine transporter SPECT studies. J Nucl Med (2005) 1.32
Carbon 11-labeled pittsburgh compound B positron emission tomographic amyloid imaging in patients with APP locus duplication. Arch Neurol (2008) 1.31
Automated quantitative gait analysis in animal models of movement disorders. BMC Neurosci (2010) 1.31
The role of 68Ga-DOTATATE PET/CT in suspected neuroendocrine tumors. J Nucl Med (2012) 1.31
Positron emission tomography-computed tomography (PET-CT) after induction therapy is highly predictive of patient outcome in follicular lymphoma: analysis of PET-CT in a subset of PRIMA trial participants. J Clin Oncol (2011) 1.30
Striatal dopamine D1 and D2 receptors in burning mouth syndrome. Pain (2003) 1.29
Dopamine in amygdala gates limbic processing of aversive stimuli in humans. Nat Neurosci (2008) 1.29
Lower striatal dopamine D2/3 receptor availability in obese compared with non-obese subjects. EJNMMI Res (2011) 1.29
SNM practice guideline for dopamine transporter imaging with 123I-ioflupane SPECT 1.0. J Nucl Med (2011) 1.28
Value of O-(2-[18F]fluoroethyl)- L-tyrosine PET for the diagnosis of recurrent glioma. Eur J Nucl Med Mol Imaging (2004) 1.28
Prediction of Alzheimer disease in subjects with amnestic and nonamnestic MCI. Neurology (2013) 1.27
Decreased brain serotonin 5-HT1A receptor availability in medication-naive patients with major depressive disorder: an in-vivo imaging study using PET and [carbonyl-11C]WAY-100635. Int J Neuropsychopharmacol (2007) 1.27
68Ga-DOTATATE PET/CT for the early prediction of response to somatostatin receptor-mediated radionuclide therapy in patients with well-differentiated neuroendocrine tumors. J Nucl Med (2010) 1.26
Quantification of Parkinson's disease-related network expression with ECD SPECT. Eur J Nucl Med Mol Imaging (2006) 1.24
Brain tumour imaging with PET: a comparison between [18F]fluorodopa and [11C]methionine. Eur J Nucl Med Mol Imaging (2003) 1.23
Striatal dopamine transporter availability associated with polymorphisms in the dopamine transporter gene SLC6A3. J Nucl Med (2008) 1.23
Neuroendocrine tumor recurrence: diagnosis with 68Ga-DOTATATE PET/CT. Radiology (2013) 1.22
Regional expansion of hypometabolism in Alzheimer's disease follows amyloid deposition with temporal delay. Biol Psychiatry (2011) 1.22
A European multicentre PET study of fibrillar amyloid in Alzheimer's disease. Eur J Nucl Med Mol Imaging (2012) 1.21
Evaluation of anatomy based reconstruction for partial volume correction in brain FDG-PET. Neuroimage (2004) 1.21
Quantitative accuracy of dopaminergic neurotransmission imaging with (123)I SPECT. J Nucl Med (2003) 1.21
High opiate receptor binding potential in the human lateral pain system. Neuroimage (2005) 1.20
Evaluation of three MRI-based anatomical priors for quantitative PET brain imaging. IEEE Trans Med Imaging (2011) 1.20
Postictal psychosis in temporal lobe epilepsy. Epilepsia (2003) 1.20
European multicentre database of healthy controls for [123I]FP-CIT SPECT (ENC-DAT): age-related effects, gender differences and evaluation of different methods of analysis. Eur J Nucl Med Mol Imaging (2012) 1.19